Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
929.47B
Market cap929.47B
Price-Earnings ratio
42.92
Price-Earnings ratio42.92
Dividend yield
0.63%
Dividend yield0.63%
Average volume
2.45M
Average volume2.45M
High today
$1,003.22
High today$1,003.22
Low today
$975.89
Low today$975.89
Open price
$980.44
Open price$980.44
Volume
1.98M
Volume1.98M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

The current Eli Lilly(LLY) stock price is $984.01, with a market capitalization of 929.47B. The stock trades at a price-to-earnings (P/E) ratio of 42.92 and offers a dividend yield of 63.2%.

As of 2026-03-14, Eli Lilly(LLY) stock has fluctuated between $975.89 and $1,003.22. The current price stands at $984.01, placing the stock +0.8% above today's low and -1.9% off the high.

Eli Lilly(LLY) shares are trading with a volume of 1.98M, against a daily average of 2.45M.

During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,133.95 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $623.78 at its lowest and $1,133.95 at its peak.

LLY News

Simply Wall St 20h
Lilly’s China Bet and U.S. Access Push Could Be A Game Changer For Eli Lilly

In early March 2026, Eli Lilly announced a US$3.00 billion, decade-long expansion in China centered on local production and supply for its oral obesity pill orf...

Lilly’s China Bet and U.S. Access Push Could Be A Game Changer For Eli Lilly
Nasdaq 1d
Is Eli Lilly's Weight Loss Empire in Trouble?

Key Points Several pharmaceutical companies have recently posted encouraging clinical data for their weight-loss candidates. However, most of these won't be a...

Is Eli Lilly's Weight Loss Empire in Trouble?
TipRanks 1d
Lilly Advances Eloralintide Study in High-Risk Kidney Patients: What Investors Should Know

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. This early Eli Lilly study, titled “A Phase 1, Multicenter, Parallel-Design, S...

Analyst ratings

80%

of 35 ratings
Buy
80%
Hold
17.1%
Sell
2.9%

More LLY News

Benzinga 1d
Kroger Shares Rise, Pharmacies Add Eli Lilly Zepbound KwikPen - Kroger, Eli Lilly - Benzinga

...

Kroger Shares Rise, Pharmacies Add Eli Lilly Zepbound KwikPen - Kroger, Eli Lilly - Benzinga
Simply Wall St 2d
Eli Lilly’s China Bet On Orforglipron Reshapes Obesity Drug Narrative

Eli Lilly (NYSE:LLY) announced a US$3b, decade-long plan to localize production and expand supply chain capacity for its oral obesity drug candidate, orforglipr...

Eli Lilly’s China Bet On Orforglipron Reshapes Obesity Drug Narrative
Benzinga 2d
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12

Eli Lilly and Co (NYSE:LLY) on Thursday issued a public warning about potential safety risks linked to compounded tirzepatide products that are mixed with vitam...

Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
Seeking Alpha 3d
Eli Lilly warns of safety risks from compounded obesity drugs after finding impurity

Eli Lilly (LLY) has issued a public warning about potential safety risks associated with compounded tirzepatide mixed with vitamin B12. Lilly tested compounded...

Eli Lilly warns of safety risks from compounded obesity drugs after finding impurity
TipRanks 3d
Lilly issues letter warning potential risks of compounded tirzepatide, B12

Lilly is issuing a public warning about potential safety risks associated with compounded tirzepatide mixed with vitamin B12. As part of the company’s commitmen...

Simply Wall St 3d
Is Eli Lilly Still Reasonably Priced After Its Strong Multi Year Share Price Rally

If you are wondering whether Eli Lilly's current share price still makes sense after a huge run in recent years, you are not alone. The stock closed at US$999....

Is Eli Lilly Still Reasonably Priced After Its Strong Multi Year Share Price Rally
TipRanks 3d
The Not So Subtle Reason Why Eli Lilly Is Investing $3 Billion in China

Eli Lilly (LLY) has pledged to invest $3 billion in China over the next decade as the U.S. pharmaceutical giant seeks regulatory approval for its new weight-los...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.